查詢結果分析
相關文獻
- Haloperidol及Risperidone治療精神分裂症的療效與成本比較
- 抗精神病藥物對精神分裂症病人錐體外症候群及大腦紋狀體D[feaf]接受體密度之影響
- 譫妄症臨床診治
- 修訂版長谷川氏痴呆量表的效度研究
- Clozapine 急性中毒引起抗精神病藥物惡性症候羣:一例報告
- Risperidone 引發抗精神病藥物惡性症候羣:一例報告
- 抗精神病藥物惡性症候群及其治療
- 精神分裂病的藥物治療:美國的現況
- The Effects of Haloperidol and Sulpiride on Apomorphine-induced Locomotor Activity in Rats
- 住院年老病患的認知功能
頁籤選單縮合
題名 | Haloperidol及Risperidone治療精神分裂症的療效與成本比較=Comparison of Effectiveness and Cost of Haloperidol and Risperidone in Outpatients with Chronic Schizophrenia |
---|---|
作者 | 廖以誠; 楊延光; 陳柏熹; 李怡慧; 李毅達; 葉宗烈; 陳純誠; | 書刊名 | 臺灣精神醫學 |
卷期 | 17:4 2003.12[民92.12] |
頁次 | 頁293-301 |
分類號 | 418.21 |
關鍵詞 | 抗精神病藥物; 錐體外症狀; 經濟成本; 認知功能; Antipsychotics; Extrapyramidal side effects; Economic cost; Cognitive function; |
語文 | 中文(Chinese) |
中文摘要 | 目的:探討門診使用Haloperidol或Risperidone治療之精神分裂症病患其錐體外症狀、認知功能與醫療經濟成本之差異。 方法:採自然性研究方法,收集Haloperidol治療個案32人(簡稱H組),Risperidone 治療個案40人(簡稱R組),比較兩組病人在基本智力(SPM)、精神症狀(PANSS)、錐體外症狀(ESRS)、認知功能(WCST 、CPT)之得分、Trihexylphenidyl使用劑量以及直接與間接醫療經濟成本之差異。 結果:R組SPM的分數顯著較H組高,兩組在PANSS、WCST與CPT得分無差別。雖然R組在ESRS的分數較低(p=.12),且Trihexylphenidyl使用劑量也較H 組低(p=.08),但均未達統計顯著。不過R組醫療經濟成本明顯較H組高。 結論:慢性精神分裂症患者使用Risperidone治療雖然經濟成本較高,但在錐體外症狀與抗膽鹼藥物使用劑量上,有症狀較輕與劑量較低的傾向,然未達統計顯著差異。兩組個案之認知功能無顯著差異。 |
英文摘要 | Objectives: This study compared extrapyramidal side effects and cognitive function in haloperidol- treated and risperidone-treated outpatients with chronic schizophrenia as well as the economic costs of these two treatments. Methods: Thirtytwo haloperidol-treated and 40 risperidone-treated patients (aged 18 to 65) with a diagnosis of schizophrenia received treatment with the same antipsychotic drug formore than one year, in a naturalistic outpatient clinic setting of 3 general hospitals were recruited. The differences of these two groups in scores of PANSS, ESRS, WCST, CPT, SPM, dosage of trihexylphenidyl, and economic costs were analyzed. Results: There were no differences in PANSS,WSCT and CPT scores between the two groups. Although the risperidone-treated group had a lower ESRS score (p=0.12) and a smaller dosage of trihexylphenidyl (p=0.08), these differences were not significant. The risperidone -treated group had significantly higher SPM score and economic costs. Conclusions: Risperidonetreated chronic schizophrenic patients had significantly higher economic cost, but had a lower tendency to develop extrapyramidal side effects and required a smaller dosage of trihexylphenidyl, although these trends were not significant. There were no differences incognitive function between risperidone-treated and haloperidol-treated patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。